Bruker Corporation
BRKR
Rank in Stocks
#2334
Bruker Corporation stands as a prominent global developer, manufacturer, and... Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
Share Price
$55.38
Last synced: 2026-10-19
Market Cap
$8.44B
Change (1 day)
1.05%
Change (1 year)
45.30%
Country
US
Trade Bruker Corporation (BRKR)
Category
Healthcare
P/E ratio for Bruker Corporation (BRKR)
P/E ratio as of October 2026 TTM: -79.54
According to Bruker Corporation latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -79.54. At the end of 2023 the company had a P/E ratio of 25.18.
P/E ratio history for Bruker Corporation from 2000 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -79.54 | -202.99% |
| 2024 | 77.23 | 206.68% |
| 2023 | 25.18 | -26.47% |
| 2022 | 34.24 | -25.31% |
| 2021 | 45.85 | -12.87% |
| 2020 | 52.62 | 31.18% |
| 2019 | 40.11 | 55.02% |
| 2018 | 25.88 | -62.52% |
| 2017 | 69.03 | 210.18% |
| 2016 | 22.26 | -44.61% |
| 2015 | 40.18 | -30.80% |
| 2014 | 58.06 | 41.29% |
| 2013 | 41.09 | 25.89% |
| 2012 | 32.64 | 46.67% |
| 2011 | 22.26 | -22.20% |
| 2010 | 28.61 | 17.80% |
| 2009 | 24.28 | 139.77% |
| 2008 | 10.13 | -85.11% |
| 2007 | 68.00 | 64.84% |
| 2006 | 41.25 | -69.31% |
| 2005 | 134.39 | -370.97% |
| 2004 | -49.60 | 85.31% |
| 2003 | -26.76 | -35.09% |
| 2002 | -41.23 | -116.97% |
| 2001 | 243.02 | -58.74% |
| 2000 | 589.00 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 33.11 | -141.62% |
US
|
|
| 21.39 | -126.89% |
IE
|
|
| 28.94 | -136.39% |
US
|
|
| 17.34 | -121.80% |
US
|
|
| - | - |
DE
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.